When further comparing the clinically relevant markers LAG-3 and PD-1, the intratumoral immune cells in the CD3high subgroup showed a higher expression of CD4+ LAG-3 (p = .01, median 2.8% vs .2%), CD8+ LAG-3 (p = .02 median 6.4% vs .9%), CD4+ PD-1 (p = .02, median 50.6% vs 18.1%) and CD8+ PD-1 (p = .008, median 71.4% vs 25.5%), whereas no difference was found in the NKhigh group between the tumor and the healthy tissue (Figure 3e,f and Supplementary Fig. S5B, respectively). This evidence concerns the gene CD4 and neoplasm.